Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
42.3M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
21.4M
-
Shares change
-
+1.38M
-
Total reported value, excl. options
-
$387M
-
Value change
-
+$39.2M
-
Put/Call ratio
-
0.2
-
Number of buys
-
63
-
Number of sells
-
-22
-
Price
-
$18.07
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) as of Q2 2023
103 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.4M shares
of 42.3M outstanding shares and own 50.71% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (2.55M shares), Vivo Capital, LLC (2.26M shares), BlackRock Inc. (2.2M shares), COWEN AND COMPANY, LLC (2M shares), Frazier Life Sciences Management, L.P. (1.79M shares), TANG CAPITAL MANAGEMENT LLC (1.78M shares), Cormorant Asset Management, LP (1.42M shares), PERCEPTIVE ADVISORS LLC (1.3M shares), VANGUARD GROUP INC (1.24M shares), and GEODE CAPITAL MANAGEMENT, LLC (445K shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.